Three-statement Excel model · 22 quarters and 5 fiscal years of history · 10 quarters and 5 fiscal years of projections
About the MRK model
This three-statement Excel model covers Merck & Co., Inc. (MRK): its income statement, balance sheet and cash flow statement. It holds 22 quarters and 5 fiscal years of history and 10 quarters and 5 fiscal years of projections.
Projected revenue is built from KPI drivers: Keytruda franchise on a year-over-year growth rate, split into subcutaneous QLEX by a conversion rate with IV as the residual, plus eleven other product buckets and Animal Health each on their own growth rate, across 2 segments.
Beyond the income statement, the workbook has these sections: Revenue by Product and Segment, KPI Drivers, Balance Sheet and Cash Flow Statement.
Model thesis: Subcutaneous conversion is the whole bridge: base IV Keytruda turned negative in 2Q26, and FY2029E revenue sits 8.8% under a Street that models no cliff at all through the December 2028 US patent expiry
On October 19, 2026, the model passed checks C13 (every subtotal reconciles to the reported figure at $0), C14 (every projected revenue cell traces to a KPI driver row) and C15 (each driver ends in a rate, a count or a historical anchor, never a typed-in projected dollar level). It was last updated September 26, 2026.
Income statement preview
Columns 2023–2025 are actual results and 2026E–2028E are our estimates. Figures were recalculated in Excel on September 26, 2026. Dollars in millions, except per share data.
| Income Statement | ||||||
|---|---|---|---|---|---|---|
| Actual | Estimate | |||||
| 2023 | 2024 | 2025 | 2026E | 2027E | 2028E | |
| Total Revenue | $60,115.0 | $64,168.0 | $65,011.0 | $66,781.8 | $69,486.9 | $72,710.1 |
| Less: Cost of Sales | ($16,126.0) | ($15,193.0) | ($16,382.0) | ($17,485.3) | ($18,363.2) | ($19,433.3) |
| Gross Profit | $43,989.0 | $48,975.0 | $48,629.0 | $49,296.5 | $51,123.7 | $53,276.8 |
| Less: Selling, General and Administrative | (10,504.0) | (10,816.0) | (10,733.0) | (11,398.8) | (11,883.3) | (12,580.1) |
| Less: Research and Development - Core | (19,122.0) | (14,482.0) | (15,789.0) | (17,163.6) | (17,371.7) | (17,814.0) |
| Less: Research and Development - Acquired IPR&D | (11,409.0) | (3,456.0) | 0.0 | (13,811.0) | (2,000.0) | (2,000.0) |
| Less: Research and Development | ($30,531.0) | ($17,938.0) | ($15,789.0) | ($30,974.6) | ($19,371.7) | ($19,814.0) |
| Less: Restructuring Costs | (599.0) | (309.0) | (889.0) | (896.0) | (600.0) | (400.0) |
| Total Operating Expenses | ($41,634.0) | ($29,063.0) | ($27,411.0) | ($43,269.4) | ($31,855.1) | ($32,794.1) |
| Operating Income | $2,355.0 | $19,912.0 | $21,218.0 | $6,027.0 | $19,268.6 | $20,482.7 |
| Interest Income | 365.0 | 415.0 | 343.0 | 167.7 | 308.0 | 443.3 |
| Less: Interest Expense | (1,146.0) | (1,271.0) | (1,357.0) | (2,091.0) | (2,156.2) | (2,162.1) |
| Less: Exchange Losses | (370.0) | (227.0) | (323.0) | (155.0) | (160.0) | (160.0) |
| Income from Investments in Equity Securities, net | 340.0 | 14.0 | 368.0 | 411.0 | 0.0 | 0.0 |
| Net Periodic Defined Benefit Plan Credit | 498.0 | 633.0 | 615.0 | 522.0 | 520.0 | 520.0 |
| Other Non-Operating Income (Expense), net | (153.0) | 460.0 | 203.0 | 199.0 | 200.0 | 200.0 |
| Less: Other (Income) Expense, net | ($466.0) | $24.0 | ($151.0) | ($946.2) | ($1,288.2) | ($1,158.9) |
| Total Costs, Expenses and Other | ($58,226.0) | ($44,232.0) | ($43,944.0) | ($61,701.0) | ($51,506.5) | ($53,386.2) |
| Income Before Taxes | $1,889.0 | $19,936.0 | $21,067.0 | $5,080.8 | $17,980.4 | $19,323.8 |
| Less: Taxes on Income | ($1,512.0) | ($2,803.0) | ($2,804.0) | ($2,618.2) | ($2,697.4) | ($2,878.7) |
| Net Income from Continuing Operations | $377.0 | $17,133.0 | $18,263.0 | $2,462.6 | $15,283.1 | $16,445.1 |
| Less: Net Income Attributable to Noncontrolling Interests | (12.0) | (16.0) | (9.0) | 5.0 | 0.0 | 0.0 |
| Income from Discontinued Operations, Net of Tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Income Attributable to Merck & Co., Inc. | $365.0 | $17,117.0 | $18,254.0 | $2,467.6 | $15,283.1 | $16,445.1 |
| Ratios & Assumptions | ||||||
| YoY Total Revenue Growth | 1.4% | 6.7% | 1.3% | 2.7% | 4.1% | 4.6% |
| Gross Margin | 73.2% | 76.3% | 74.8% | 73.8% | 73.6% | 73.3% |
| Operating Margin | 3.9% | 31.0% | 32.6% | 9.0% | 27.7% | 28.2% |
| Net Margin (continuing operations) | 0.6% | 26.7% | 28.1% | 3.7% | 22.0% | 22.6% |
| Effective Tax Rate | 80.0% | 14.1% | 13.3% | 51.5% | 15.0% | 14.9% |
The full workbook adds 22 historical and 10 projected quarters, plus Revenue by Product and Segment · KPI Drivers · Balance Sheet · Cash Flow Statement — every subtotal a live formula, every projection traced to a driver.
Merck & Co. research
Aardvark Labs Capital Research has published 5 reports on Merck & Co. (MRK). The latest is the Q3 2026 Earnings Recap, published October 31, 2026, rated Underperform.
Downgrading Merck to Underperform: The Beat Was Purchase Timing and a Tax Rate, 2027 Is Another Investment Year, and the Stock Has Run Past Fair Value
Methodology
Every projected revenue cell traces to a KPI/driver row (C14). Terminal driver cells are rates, counts, or historical anchors — never typed-in projected dollar levels (C15). Every subtotal-vs-reported reconciliation row ties to $0 (C13). Each model is written per-ticker against its actual schema — no cloning, no level-input shortcuts.